Diet 'wonder drug' approved

O'Driscoll, Cath
July 2006
ICIS Chemical Business;7/10/2006, Vol. 1 Issue 27, p31
Trade Publication
The article reports that the weight-loss drug Acomplia (rimonabant) from Sanofi-Aventis has been approved for use in all 25 European Union member states. The first in a class of drugs called CB1 blockers, the pill has been licensed for use as an adjunct to diet for obese or overweight patients with complicating risk factors such as type II diabetes and heart disease.


Related Articles

  • Can a Pill Save You from Yourself? Hirshberg, Charles // Men's Health;Apr2006, Vol. 21 Issue 3, p140 

    This article provides information on the drug Acomplia. The drug could well be just the first of a whole new class of drugs that work by taking advantage of one of the most intriguing biological discoveries of the past 20 years, the endocannabinoid system. To study these sorts of effects,...

  • An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in overweight and obese people with type 2 diabetes. Chyun, Deborah // Evidence Based Nursing;Jan2008, Vol. 11 Issue 1, p16 

    QUESTION In overweight or obese people with type 2 diabetes, does an intensive lifestyle intervention reduce weight and cardiovascular disease risk factors? METHODS Design: randomised controlled trial (Action for Health in Diabetes [Look AHEAD] trial). Allocation: {concealed}. Blinding: {data...

  • Obesity Drug In the Wings.  // Nutrition Business Journal;Mar2005, Vol. 10 Issue 3, p10 

    Reports on French company Sanofi-Aventis' preparation for the launch of a weight loss drug called rimonabant, brand name Acomplia, in 2006. Drug's targeting of the endocannabinoid system in the brain, believed to play a role in regulating appetite; Estimated sales of the drug in the U.S. if it...

  • Review: Surgical Treatment of Type 2 Diabetes. Hellín Gil, María Dolores; Pujante Alarcón, Pedro; López Ruiz, Alfonso; Ángeles Ibañez, María; Hernández Torres, Alicia; Hernández Cascales, Ana Belén // Pharmacology & Pharmacy;Jan2014, Vol. 5 Issue 1, p24 

    In the last decades we have witnessed a significant increase in the incidence of type 2 diabetes mellitus, and obesity in parallel. So 90% of patients with Diabetes Mellitus type 2 (DM2) are obese. Changes in lifestyle (diet and exercise), behavioral therapies or the use of certain anti-obesity...

  • A Randomised Trial of a Weight Loss Intervention for Overweight and Obese People Diagnosed with Coronary Heart Disease and/or Type 2 Diabetes. Gallagher, Robyn; Kirkness, Ann; Zelestis, Elizabeth; Hollams, Dan; Kneale, Caryn; Armari, Elizabeth; Bennett, Tania; Daly, John; Tofler, Geoff // Annals of Behavioral Medicine;Aug2012, Vol. 44 Issue 1, p119 

    Background: Weight reduction limits disease progression in obese people with coronary heart disease (CHD) and/or type 2 diabetes mellitus (T2DM). Purpose: To test a 16-week group-based weight reduction intervention combining exercise, diet and behaviour change strategies aimed to increase...

  • Medications for Weight Loss in Patients with Type 2 Diabetes Mellitus. Kachowski, Larisa; Over, Darrell R.; Kefeng Qiu // American Family Physician;3/15/2012, Vol. 85 Issue 6, p633 

    The article discusses weight-loss medications that are effective and safe for use in patient with type 2 diabetes mellitus. Both fluoxetine (Prozac) and orlistat (Xenical) can produce modest short-term weight loss. The usefulness of topiramate (Topamax) was limited by potential psychiatric and...

  • The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes. Hollander, Priscilla // U.S. Endocrinology;Winter2013, Vol. 9 Issue 2, p101 

    The prevalence of diabetes continues to rise, following the rising rates of obesity. Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing long-term complications associated with the disease. Weight gain is also an...

  • Why you should drop those 15 extra pounds. Colino, Stacey // Redbook;Jan2003, Vol. 200 Issue 1, p38 

    Discusses the health benefits of losing weight. Ways to avoid the development of type II diabetes; Importance of losing weight to prevent heart disease; Risks posed by weight increase in developing a host of cancers.

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics